ECE2023 Eposter Presentations Reproductive and Developmental Endocrinology (48 abstracts)
Growth hormone treatment in SGA children leads to worsening of insulin resistance parameters without beneficial effects on lipid profile – a 3-year retrospective study
Maria Silva 1,2,3 , Joao Sergio Neves 1,2,3,4 , Carla Costa 5 , Rita Santos Silva 5 , Sofia Ferreira 5 , Davide Carvalho 1,2,3 & Cíntia Castro-Correia 5
1São João Universitary Hospital Center, Serviço de Endocrinologia, Diabetes e Metabolismo, Porto, Portugal; 2Faculdade de Medicina da Universidade do Porto - FMUP, Porto, Portugal; 3i3S - Instituto de Investigação e Inovação em Saúde da Universidade do Porto, Porto, Portugal; 4Faculdade de Medicina da Universidade do Porto - FMUP, Departamento de Cirurgia e Fisiologia, Porto, Portugal; 5São João Universitary Hospital Center, Unidade de Endocrinologia Pediátrica, Porto, Portugal
Background: Children who were born small for gestational age (SGA) and who do not have adequate catch-up growth until 4 years old have indication for treatment with recombinant human growth hormone (rhGH). The metabolic consequences of this treatment are relatively unknown.
Objective: To evaluate the effect of rhGH treatment on insulin sensitivity and lipid profile.
Materials and methods: A retrospective observational study of children born SGA who underwent rhGH therapy was performed. Data was assessed before treatment and yearly (three-year follow-up).
Results: A total of 25 SGA children were included. The median age of the children at rhGH treatment was 5.0 (IQR 4.0-9.0) years old. A statistical significant increase in IGF-1 was observed in all years of follow-up. Fasting plasma glucose increased during follow-up, with significant differences in first and third year. Fasting insulin and HOMA-IR values tended to increase, with significant differences observed during the second and third year. The analysis on lipid profile (total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and triglycerides) was not statistically significant. Height (Z-score) increased significantly (basal: −3.0; first year: -2.3; second year: −2.1; third-year -2.1). The effect of rhGH treatment on stature (ΔZ-core) was not relatable with insulin resistance, lipid profile or age at beginning of treatment.
Conclusion: Fasting plasma glucose, fasting insulin and HOMA-IR increased significantly during follow-up. No significant differences were found on lipid profile. No relation was found between the effect on height and metabolic consequences.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more